Forbion, a global life sciences venture capital firm focused on Europe, has raised over €2bn ($2.2bn) across its two newest funds, Forbion Growth Opportunities III and Forbion Ventures VII, bringing total assets under management to €5bn ($5.5bn).
Both funds exceeded their original target sizes reaching €1.2bn ($1.3bn) and €890m ($980m) respectively, and will each target investments in 15 portfolio companies.
The fundraising builds on Forbion’s successful track-record of generating consistently impactful returns based on an investment strategy focused on companies with strong fundamentals, anchored in unique science and deep due diligence, while its platform approach enables its funds to support biotechs through company building (Ventures funds) and company expansion (Growth Opportunities funds).
Since its launch over two decades ago, Forbion has made 128 investments, while the firm’s portfolio companies have contributed to advancing medical science and innovation through the development of many breakthrough therapies, including pioneering the development of new technologies such as gene and immune therapies, and via 256 scientific publications.
